EUVIMEDEUVIMED entdecken
Crossref

Comparison of Efficacy of Baricitinib and Dupilumab in the Treatment of Chinese Moderate-To-Severe Atopic Dermatitis: A Retrospective Study

Bo Liu, Xiaoting Song, Shuanglu Liao, Tingting Luan, Zuotao Zhao

International Archives of Allergy and Immunology · 2023

DOI: 10.1159/000530394 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Archives of Allergy and Immunology, 2023. Verfasst von Bo Liu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China, liubo_bjmu@163.com. Hauptthemen laut MEDLINE: Dermatitis, Atopic. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The treatment of atopic dermatitis (AD) patients with insufficient response or intolerance to topical medication remains clinical challenges, and there is a paucity of head-to-head trials comparing the efficacy of novel biological agents such as JAK inhibitor and antibody.

Methods

To compare the efficacy of selective JAK1/JAK2 inhibitor baricitinib and interleukin-4 monoclonal antibody dupilumab in the treatment of patients with moderate-to-severe AD, a retrospective cohort study method was adopted. Clinical data from June 2020 to April 2022 were systematically reviewed. Eligible patients who received baricitinib or dupilumab were screened according to the following inclusion criteria: (1) age ≥ 18 years; (2) moderate-to-severe AD: baseline investigator global assessment (IGA) score ≥ 3, baseline eczema area and severity index (EASI) score ≥ 16; (3) poor response or intolerance to at least one topical drug in the past 6 months; (4) no topical glucocorticoids were used in the past 2 weeks and no systematic treatment was given in the past 4 weeks. Patients of the baricitinib group were treated with oral baricitinib in doses of 2 mg per day for 16 weeks, and patients of the dupilumab group were treated with standardized use of dupilumab for 16 weeks, with the initial 600 mg subcutaneous injection and the following 300 mg subcutaneous injection every 2 weeks. The clinical efficacy score indexes including the IGA score, EASI score, and Itch Numeric Rating Scale (NRS) score. These scores at 0, 2, 4, 8, 12, and 16 weeks after the start of treatment were collected.

Results

A total of 54/45 patients treated with baricitinib/dupilumab were included. There was no significant difference in the decrease of all scores between the two groups at the 4th week (p > 0.05). There was no difference in the EASI score and Itch NRS score (p > 0.05), but the IGA score of the baricitinib group was lower at the 16th week (Z = 4.284, p < 0.001). Within the first 4 weeks, the Itch NRS score of the baricitinib group decreased rapidly, but with the prolongation of treatment time, there was no significant difference between the two groups at the 16th week (Z = 1.721, p = 0.085).

Conclusions

The efficacy of baricitinib at a dose of 2 mg daily was similar to dupilumab, and the improvement in pruritus was significantly faster in the early stage of treatment (the first 4 weeks) than that of dupilumab.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Dermatitis, AtopicHumansEast Asian PeopleImmunoglobulin APruritusRetrospective StudiesSeverity of Illness IndexTreatment OutcomeAzetidinesPurinesPyrazolesSulfonamidesAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

Atopic dermatitisBaricitinibDupilumabRetrospective cohort study

Substanzen

Immunoglobulin AbaricitinibAzetidinesPurinesPyrazolesSulfonamidesdupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China, liubo_bjmu@163.com.
  • Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China, liubo_bjmu@163.com.
  • National Clinical Research Center for Skin and Immune Diseases, Beijing, China, liubo_bjmu@163.com.
  • Department of Dermatology and Venerology, Peking University First Hospital, Beijing, China.
  • Beijing Key Laboratory of Molecular Diagnosis on Dermatoses, Beijing, China.
  • National Clinical Research Center for Skin and Immune Diseases, Beijing, China.

Zitieren

APA

Liu, B., Song, X., Liao, S., Luan, T., & Zhao, Z. (2023). Comparison of Efficacy of Baricitinib and Dupilumab in the Treatment of Chinese Moderate-To-Severe Atopic Dermatitis: A Retrospective Study. International Archives of Allergy and Immunology. https://doi.org/10.1159/000530394

Vancouver

Liu B, Song X, Liao S, Luan T, Zhao Z. Comparison of Efficacy of Baricitinib and Dupilumab in the Treatment of Chinese Moderate-To-Severe Atopic Dermatitis: A Retrospective Study. International Archives of Allergy and Immunology. 2023. doi:10.1159/000530394

BibTeX
@article{Liu2023,
  author = {Liu, Bo and Song, Xiaoting and Liao, Shuanglu and Luan, Tingting and Zhao, Zuotao},
  title = {Comparison of Efficacy of Baricitinib and Dupilumab in the Treatment of Chinese Moderate-To-Severe Atopic Dermatitis: A Retrospective Study},
  journal = {International Archives of Allergy and Immunology},
  year = {2023},
  doi = {10.1159/000530394}
}
Kostenlos starten →